智通财经网·2026-02-12 07:38Core Viewpoint - Credit Suisse has downgraded the earnings forecast for Tigermed (03347) for the fiscal year 2027 by 7% due to increased uncertainty regarding long-term investment returns [1] Group 1: Earnings Forecast and Ratings - The target price for Tigermed's H-shares has been reduced from HKD 68.2 to HKD 59.9 [1] - The target price for Tigermed's A-shares has been lowered from RMB 81.9 to RMB 72 [1] - The company continues to hold a "Outperform" rating despite the downgrade [1] Group 2: Market Conditions and Company Performance - Tigermed's order situation has shown improvement, but the market is more focused on the efficiency of order conversion into revenue and the company's ability to realize investment returns [1] - Short-term positive factors have already been reflected in the stock price, leading to a belief that the risk and return have become balanced [1]